Heated tobacco products (HTPs) and IQOS

2025

2025: “Keep it a secret”: Leaked Documents Suggest Philip Morris International, and Its Japanese Affiliate, Continue to Exploit Science for Profit

2025: Understanding Heated Tobacco Products HTPs

2024

2024: Comparison of Publications on Heated Tobacco Products With Conventional Cigarettes and Implied Desirability of the Products According to Tobacco Industry Affiliation: A Systematic Review

2024: Association of conventional cigarette smoking, heated tobacco product use and dual use with hypertension

2023

2023: Heated Tobacco Products: Insights into Composition and Toxicity

2022

2022: Heated tobacco products: recommendations from the Austrian council on smoking and health

2022: Heated tobacco products do not help smokers quit or prevent relapse: a longitudinal study in Japan

2022: Should IQOS Emissions Be Considered as Smoke and Harmful to Health? A Review of the Chemical Evidence

2021

2021: Analysis of FDA’s IQOS marketing authorisation and its policy impacts

2020

2020: Acute Eosinophilic Pneumonia Induced by Switching from Conventional Cigarette Smoking to Heated Tobacco Product Smoking

2020: Heated tobacco products: a brief

2020: Heat-not-burn tobacco products: an emerging threat to cardiovascular health

2020: Global Marketing of IQOS The Philip Morris Campaign to Popularize “Heat Not Burn” Tobacco

2020: @FDAtobacco authorized sales of Philip Morris’ IQOS despite scientific evidence of its health Risks

2020: Heated tobacco products: information sheet – 2nd edition

2019

2019: Heat-not-burn cigarettes induce fulminant acute eosinophilic pneumonia requiring extracorporeal membrane oxygenation

2019: Prevalence, Use Behaviors, and Preferences among Users of Heated Tobacco Products: Findings from the 2018 ITC Japan Survey

2019: iQOS: evidence of pyrolysis and release of a toxicant from plastic

2019: Passive exposure to pollutants from conventional cigarettes and new electronic smoking devices (IQOS, e-cigarette) in passenger cars

2018

2018: Assessment of industry data on pulmonary and immunosuppressive effects of IQOS

2018: Heated tobacco products: another tobacco industry global strategy to slow progress in tobacco control

2018: The Union’s position on heated tobacco products (HTP)

2018: IQOS: examination of Philip Morris International’s claim of reduced exposure

2018: PMI’s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes

2018: Heated tobacco products (HTPs) information sheet

2018: Heated tobacco products (HTPs) market monitoring information sheet

2017

2017: Heat-Not-Burn Tobacco Cigarettes: Smoke by Any Other Name

2016

2016: Acute eosinophilic pneumonia following heat‐not‐burn cigarette smoking